Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9768, pp. 813 - 822
Summary Background Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL,...
Internal Medicine | BREAST-CANCER | CONTROLLED-TRIALS | LONG-TERM | SURVIVAL | MEDICINE, GENERAL & INTERNAL | CONTROLLED PHASE-II | MULTICENTER | THERAPY | PREVENTION | SKELETAL COMPLICATIONS | CARCINOMA | Prostatic Neoplasms - pathology | Bone Density Conservation Agents - adverse effects | Prostatic Neoplasms - surgery | Humans | Imidazoles - adverse effects | Middle Aged | Antibodies, Monoclonal - adverse effects | Bone Density Conservation Agents - therapeutic use | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Male | Denosumab | Orchiectomy | Antibodies, Monoclonal, Humanized | Diphosphonates - therapeutic use | Aged | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | RANK Ligand - therapeutic use | Diphosphonates - adverse effects | RANK Ligand - adverse effects | Usage | Patient outcomes | Zoledronic acid | Metastasis | Research | Drug therapy | Comparative analysis | Fees & charges | Acids | Conferences | Patient safety | Public speaking | Clinical medicine | Prostate cancer | Cancer therapies
Internal Medicine | BREAST-CANCER | CONTROLLED-TRIALS | LONG-TERM | SURVIVAL | MEDICINE, GENERAL & INTERNAL | CONTROLLED PHASE-II | MULTICENTER | THERAPY | PREVENTION | SKELETAL COMPLICATIONS | CARCINOMA | Prostatic Neoplasms - pathology | Bone Density Conservation Agents - adverse effects | Prostatic Neoplasms - surgery | Humans | Imidazoles - adverse effects | Middle Aged | Antibodies, Monoclonal - adverse effects | Bone Density Conservation Agents - therapeutic use | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Male | Denosumab | Orchiectomy | Antibodies, Monoclonal, Humanized | Diphosphonates - therapeutic use | Aged | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | RANK Ligand - therapeutic use | Diphosphonates - adverse effects | RANK Ligand - adverse effects | Usage | Patient outcomes | Zoledronic acid | Metastasis | Research | Drug therapy | Comparative analysis | Fees & charges | Acids | Conferences | Patient safety | Public speaking | Clinical medicine | Prostate cancer | Cancer therapies
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9810, pp. 39 - 46
Summary Background Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast...
Internal Medicine | ANDROGEN DEPRIVATION | ZOLEDRONIC ACID | MEDICINE, GENERAL & INTERNAL | OSTEOPROTEGERIN LIGAND | DISEASE | SKELETAL-RELATED EVENTS | COMPLICATIONS | Prostatic Neoplasms - pathology | Double-Blind Method | Prostatic Neoplasms - surgery | Humans | Antibodies, Monoclonal - adverse effects | Bone Neoplasms - secondary | Male | RANK Ligand - administration & dosage | Denosumab | Disease Progression | Prostate-Specific Antigen - blood | Orchiectomy | Antibodies, Monoclonal, Humanized | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Injections, Subcutaneous | Aged, 80 and over | Aged | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Men | Research | Diagnosis | Drug therapy | Health aspects | Prostate cancer | Family medical history | Cancer therapies | Mortality
Internal Medicine | ANDROGEN DEPRIVATION | ZOLEDRONIC ACID | MEDICINE, GENERAL & INTERNAL | OSTEOPROTEGERIN LIGAND | DISEASE | SKELETAL-RELATED EVENTS | COMPLICATIONS | Prostatic Neoplasms - pathology | Double-Blind Method | Prostatic Neoplasms - surgery | Humans | Antibodies, Monoclonal - adverse effects | Bone Neoplasms - secondary | Male | RANK Ligand - administration & dosage | Denosumab | Disease Progression | Prostate-Specific Antigen - blood | Orchiectomy | Antibodies, Monoclonal, Humanized | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Injections, Subcutaneous | Aged, 80 and over | Aged | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Men | Research | Diagnosis | Drug therapy | Health aspects | Prostate cancer | Family medical history | Cancer therapies | Mortality
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 194 - 206
In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos...
SURVIVAL | PLACEBO | PAIN | ONCOLOGY | MEN | SKELETAL-RELATED EVENTS | QUALITY-OF-LIFE | CLINICAL IMPORTANCE | CHEMOTHERAPY | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Magnetic Resonance Imaging - methods | Tomography, X-Ray Computed - methods | Male | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoplasm Invasiveness - pathology | Survival Analysis | Androgen Antagonists - therapeutic use | Quality of Life | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasm Staging | Prednisone - therapeutic use | Patient Reported Outcome Measures | Care and treatment | Corticosteroids | Patient outcomes | Analysis | Prednisone | Product development | Metastasis | Prostate cancer | Steroids
SURVIVAL | PLACEBO | PAIN | ONCOLOGY | MEN | SKELETAL-RELATED EVENTS | QUALITY-OF-LIFE | CLINICAL IMPORTANCE | CHEMOTHERAPY | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Magnetic Resonance Imaging - methods | Tomography, X-Ray Computed - methods | Male | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoplasm Invasiveness - pathology | Survival Analysis | Androgen Antagonists - therapeutic use | Quality of Life | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasm Staging | Prednisone - therapeutic use | Patient Reported Outcome Measures | Care and treatment | Corticosteroids | Patient outcomes | Analysis | Prednisone | Product development | Metastasis | Prostate cancer | Steroids
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 30, pp. 3800 - 3806
Purpose Denosumab, an anti-RANK ligand monoclonal antibody, significantly increases bone metastasis-free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and...
CONTROLLED-TRIAL | PREDNISONE | RANKL | MITOXANTRONE | ONCOLOGY | SKELETAL-RELATED EVENTS | PHASE-3 | PROGRESSION | Prostatic Neoplasms - metabolism | Humans | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Injections, Subcutaneous | Aged, 80 and over | Prostatic Neoplasms - blood | Castration - methods | Odds Ratio | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Bone Neoplasms - diagnosis | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Denosumab | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Disease-Free Survival | RANK Ligand - antagonists & inhibitors | Androgen Antagonists - therapeutic use | Aged | Guc52 | ORIGINAL REPORTS | Guc47
CONTROLLED-TRIAL | PREDNISONE | RANKL | MITOXANTRONE | ONCOLOGY | SKELETAL-RELATED EVENTS | PHASE-3 | PROGRESSION | Prostatic Neoplasms - metabolism | Humans | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Injections, Subcutaneous | Aged, 80 and over | Prostatic Neoplasms - blood | Castration - methods | Odds Ratio | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Bone Neoplasms - diagnosis | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Denosumab | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Disease-Free Survival | RANK Ligand - antagonists & inhibitors | Androgen Antagonists - therapeutic use | Aged | Guc52 | ORIGINAL REPORTS | Guc47
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 1, pp. 42 - 50
Abstract Background Previous studies have reported on prognostic factors for castration-resistant prostate cancer (CRPC); however, most of these studies were...
Urology | Castration-resistant prostate cancer | Survival | Nomogram | Bone metastases | Prognostic factors | MARKERS | UROLOGY & NEPHROLOGY | MODEL | CHEMOTHERAPY | Multivariate Analysis | Prognosis | Age Factors | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - metabolism | Denosumab - therapeutic use | Aged, 80 and over | Diphosphonates - therapeutic use | Adult | Kallikreins - blood | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Alkaline Phosphatase - blood | Double-Blind Method | Peptides - urine | Collagen Type I - urine | Proportional Hazards Models | Bone Density Conservation Agents - therapeutic use | Hemoglobins - metabolism | Prostatic Neoplasms, Castration-Resistant - metabolism | Prostate-Specific Antigen - blood | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Chemotherapy | Metastasis | Prostate cancer | Patient outcomes | Cancer
Urology | Castration-resistant prostate cancer | Survival | Nomogram | Bone metastases | Prognostic factors | MARKERS | UROLOGY & NEPHROLOGY | MODEL | CHEMOTHERAPY | Multivariate Analysis | Prognosis | Age Factors | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - metabolism | Denosumab - therapeutic use | Aged, 80 and over | Diphosphonates - therapeutic use | Adult | Kallikreins - blood | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Alkaline Phosphatase - blood | Double-Blind Method | Peptides - urine | Collagen Type I - urine | Proportional Hazards Models | Bone Density Conservation Agents - therapeutic use | Hemoglobins - metabolism | Prostatic Neoplasms, Castration-Resistant - metabolism | Prostate-Specific Antigen - blood | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Chemotherapy | Metastasis | Prostate cancer | Patient outcomes | Cancer
Journal Article
International Journal of Impotence Research, ISSN 0955-9930, 02/2018, Volume 30, Issue 1, pp. 43 - 47
This is an observational transversal cohort study in which we aim to analyze the Brazilian penis length and compare the penis size of the men self-declared as...
UROLOGY & NEPHROLOGY | CIRCUMFERENCE | SIZE | MEN | Psychological aspects | Measurement | Physiological aspects | Skin color | Penis | Men | Race | Pigments | Body measurements | Personal appearance | Skin | Reproductive system | Urogenital system
UROLOGY & NEPHROLOGY | CIRCUMFERENCE | SIZE | MEN | Psychological aspects | Measurement | Physiological aspects | Skin color | Penis | Men | Race | Pigments | Body measurements | Personal appearance | Skin | Reproductive system | Urogenital system
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 13, pp. 1812 - 1821
Abstract Background This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab....
Hematology, Oncology and Palliative Medicine | Zoledronic acid | Bone metastasis | Hypocalcaemia | Denosumab | Risk factors | CALCIUM HOMEOSTASIS | RISK | CLINICAL-FEATURES | PATHOPHYSIOLOGY | BREAST-CANCER | BISPHOSPHONATES | OVARIECTOMIZED CYNOMOLGUS MONKEYS | ONCOLOGY | PROSTATE-CANCER | SOLID TUMOR | Vitamin D Deficiency - complications | Humans | Bone Neoplasms - secondary | Hypocalcemia - blood | Denosumab - adverse effects | Incidence | Calcium - blood | Clinical Trials, Phase III as Topic | Hypocalcemia - chemically induced | Time Factors | Antineoplastic Agents - adverse effects | Retrospective Studies | Bone Neoplasms - drug therapy | Hypocalcemia - prevention & control | Diphosphonates - adverse effects | Severity of Illness Index | Hypocalcemia - epidemiology | Bone Density Conservation Agents - adverse effects | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Treatment Outcome | Biomarkers - blood | Vitamin D Deficiency - diagnosis | Hypocalcemia - diagnosis | Care and treatment | Analysis | Metastasis
Hematology, Oncology and Palliative Medicine | Zoledronic acid | Bone metastasis | Hypocalcaemia | Denosumab | Risk factors | CALCIUM HOMEOSTASIS | RISK | CLINICAL-FEATURES | PATHOPHYSIOLOGY | BREAST-CANCER | BISPHOSPHONATES | OVARIECTOMIZED CYNOMOLGUS MONKEYS | ONCOLOGY | PROSTATE-CANCER | SOLID TUMOR | Vitamin D Deficiency - complications | Humans | Bone Neoplasms - secondary | Hypocalcemia - blood | Denosumab - adverse effects | Incidence | Calcium - blood | Clinical Trials, Phase III as Topic | Hypocalcemia - chemically induced | Time Factors | Antineoplastic Agents - adverse effects | Retrospective Studies | Bone Neoplasms - drug therapy | Hypocalcemia - prevention & control | Diphosphonates - adverse effects | Severity of Illness Index | Hypocalcemia - epidemiology | Bone Density Conservation Agents - adverse effects | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Treatment Outcome | Biomarkers - blood | Vitamin D Deficiency - diagnosis | Hypocalcemia - diagnosis | Care and treatment | Analysis | Metastasis
Journal Article
World Journal of Urology, ISSN 0724-4983, 1/2016, Volume 34, Issue 1, pp. 137 - 142
The use of minilaparoscopic instruments has gained interest in recent years, permitting a less invasive treatment for many surgical procedures. Its application...
Nephrology | Ureteral | Medicine & Public Health | Renal | Surgery | Oncology | Minilaparoscopy | Urology | LAPAROSCOPIC NEPHRECTOMY | EXTRACTION | SINGLE-SITE SURGERY | UROLOGY & NEPHROLOGY | EXPERIENCE | PYELOPLASTY | OUTCOMES | PURE | Kidney - surgery | Minimally Invasive Surgical Procedures - methods | Laparoscopy - methods | Humans | Replantation - methods | Ureteral Calculi - surgery | Ureter - surgery | Urologic Surgical Procedures - methods | Nephrectomy - methods
Nephrology | Ureteral | Medicine & Public Health | Renal | Surgery | Oncology | Minilaparoscopy | Urology | LAPAROSCOPIC NEPHRECTOMY | EXTRACTION | SINGLE-SITE SURGERY | UROLOGY & NEPHROLOGY | EXPERIENCE | PYELOPLASTY | OUTCOMES | PURE | Kidney - surgery | Minimally Invasive Surgical Procedures - methods | Laparoscopy - methods | Humans | Replantation - methods | Ureteral Calculi - surgery | Ureter - surgery | Urologic Surgical Procedures - methods | Nephrectomy - methods
Journal Article
Planta Medica, ISSN 0032-0943, 03/2013, Volume 79, Issue 3/04, pp. 253 - 258
Abstract Blood fluke of the genus Schistosoma are the etiological agents of human schistosomiasis, an important neglected tropical disease that afflicts over...
Biological and Pharmacological Activity | anthelmintic activity | natural products | Schistosoma mansoni | schistosomiasis | schistosomicidal activity | (+)-limonene epoxide | CHEMISTRY, MEDICINAL | ESSENTIAL OILS | VIVO | WORMS | PLANT SCIENCES | IN-VITRO | INTEGRATIVE & COMPLEMENTARY MEDICINE | DRUGS | PHARMACOLOGY & PHARMACY | INFECTION | EGG-PRODUCTION | Schistosomiasis | Care and treatment | Limonene | Research | Chemical properties | Health aspects
Biological and Pharmacological Activity | anthelmintic activity | natural products | Schistosoma mansoni | schistosomiasis | schistosomicidal activity | (+)-limonene epoxide | CHEMISTRY, MEDICINAL | ESSENTIAL OILS | VIVO | WORMS | PLANT SCIENCES | IN-VITRO | INTEGRATIVE & COMPLEMENTARY MEDICINE | DRUGS | PHARMACOLOGY & PHARMACY | INFECTION | EGG-PRODUCTION | Schistosomiasis | Care and treatment | Limonene | Research | Chemical properties | Health aspects
Journal Article
European Urology, ISSN 0302-2838, 2009, Volume 57, Issue 1, pp. 123 - 131
Abstract Background Combination therapy with dutasteride and tamsulosin provides significantly greater benefit than either monotherapy for various...
Urology | Tamsulosin | Surgery | Combination drug therapy | Benign prostatic hyperplasia | Dutasteride | Urinary retention | Lower urinary tract symptoms | Prostate | PLACEBO | EFFICACY | SAFETY | FINASTERIDE | ENLARGEMENT | NEED | ACUTE URINARY RETENTION | UROLOGY & NEPHROLOGY | INHIBITOR | PROGRESSION | ANTIGEN | Humans | Middle Aged | Adrenergic alpha-Antagonists - therapeutic use | Male | North America | Prostatic Hyperplasia - complications | Adrenergic alpha-Antagonists - adverse effects | Time Factors | Urologic Surgical Procedures, Male | Brazil | Drug Therapy, Combination | Urinary Retention - drug therapy | Prostatic Hyperplasia - drug therapy | Enzyme Inhibitors - adverse effects | Severity of Illness Index | Double-Blind Method | Risk Assessment | Urinary Retention - etiology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | 5-alpha Reductase Inhibitors | Treatment Outcome | Azasteroids - therapeutic use | Enzyme Inhibitors - therapeutic use | Disease Progression | Azasteroids - adverse effects | Prostatic Hyperplasia - surgery | Prostatic Hyperplasia - diagnosis | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Italy | Aged | Tamsulosin hydrochloride | Drug therapy, Combination | Patient outcomes | Hypertrophy
Urology | Tamsulosin | Surgery | Combination drug therapy | Benign prostatic hyperplasia | Dutasteride | Urinary retention | Lower urinary tract symptoms | Prostate | PLACEBO | EFFICACY | SAFETY | FINASTERIDE | ENLARGEMENT | NEED | ACUTE URINARY RETENTION | UROLOGY & NEPHROLOGY | INHIBITOR | PROGRESSION | ANTIGEN | Humans | Middle Aged | Adrenergic alpha-Antagonists - therapeutic use | Male | North America | Prostatic Hyperplasia - complications | Adrenergic alpha-Antagonists - adverse effects | Time Factors | Urologic Surgical Procedures, Male | Brazil | Drug Therapy, Combination | Urinary Retention - drug therapy | Prostatic Hyperplasia - drug therapy | Enzyme Inhibitors - adverse effects | Severity of Illness Index | Double-Blind Method | Risk Assessment | Urinary Retention - etiology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | 5-alpha Reductase Inhibitors | Treatment Outcome | Azasteroids - therapeutic use | Enzyme Inhibitors - therapeutic use | Disease Progression | Azasteroids - adverse effects | Prostatic Hyperplasia - surgery | Prostatic Hyperplasia - diagnosis | Sulfonamides - therapeutic use | Sulfonamides - adverse effects | Italy | Aged | Tamsulosin hydrochloride | Drug therapy, Combination | Patient outcomes | Hypertrophy
Journal Article
World Journal of Urology, ISSN 0724-4983, 1/2015, Volume 33, Issue 1, pp. 131 - 135
To investigate whether ultrasonographic bladder wall thickness (BWT) correlates with urodynamic parameters in patients with spinal cord injury (SCI). Two...
Urodynamics | Nephrology | Medicine & Public Health | Urology/Andrology | Oncology | Bladder wall thickness | Spinal cord injury | Ultrasound | Neurogenic lower urinary tract dysfunction | ADULTS | VOIDING DYSFUNCTION | ULTRASOUND MEASUREMENT | LOWER URINARY-TRACT | CHILDREN | OUTLET OBSTRUCTION | DETERIORATION | MEN | UROLOGY & NEPHROLOGY | WEIGHT | Predictive Value of Tests | Urinary Bladder, Neurogenic - diagnostic imaging | Spinal Cord Injuries - complications | Humans | Middle Aged | Paraplegia - diagnostic imaging | Urinary Bladder, Neurogenic - etiology | Male | Urinary Bladder, Overactive - etiology | Quadriplegia - diagnostic imaging | Urinary Bladder, Neurogenic - physiopathology | Young Adult | Urodynamics - physiology | Urinary Bladder, Overactive - diagnostic imaging | Urinary Bladder, Overactive - physiopathology | Paraplegia - physiopathology | Ultrasonography | Aged, 80 and over | Adult | Female | Paraplegia - etiology | Quadriplegia - etiology | Quadriplegia - physiopathology | Spinal Cord Injuries - diagnostic imaging | Adolescent | ROC Curve | Aged | Spinal Cord Injuries - physiopathology | Medicine, Experimental | Medical research | Care and treatment | Spinal cord injuries | Ultrasound imaging | Analysis
Urodynamics | Nephrology | Medicine & Public Health | Urology/Andrology | Oncology | Bladder wall thickness | Spinal cord injury | Ultrasound | Neurogenic lower urinary tract dysfunction | ADULTS | VOIDING DYSFUNCTION | ULTRASOUND MEASUREMENT | LOWER URINARY-TRACT | CHILDREN | OUTLET OBSTRUCTION | DETERIORATION | MEN | UROLOGY & NEPHROLOGY | WEIGHT | Predictive Value of Tests | Urinary Bladder, Neurogenic - diagnostic imaging | Spinal Cord Injuries - complications | Humans | Middle Aged | Paraplegia - diagnostic imaging | Urinary Bladder, Neurogenic - etiology | Male | Urinary Bladder, Overactive - etiology | Quadriplegia - diagnostic imaging | Urinary Bladder, Neurogenic - physiopathology | Young Adult | Urodynamics - physiology | Urinary Bladder, Overactive - diagnostic imaging | Urinary Bladder, Overactive - physiopathology | Paraplegia - physiopathology | Ultrasonography | Aged, 80 and over | Adult | Female | Paraplegia - etiology | Quadriplegia - etiology | Quadriplegia - physiopathology | Spinal Cord Injuries - diagnostic imaging | Adolescent | ROC Curve | Aged | Spinal Cord Injuries - physiopathology | Medicine, Experimental | Medical research | Care and treatment | Spinal cord injuries | Ultrasound imaging | Analysis
Journal Article
Physics Letters B, ISSN 0370-2693, 09/2012, Volume 716, Issue 1, pp. 30 - 61
Results are presented from searches for the standard model Higgs boson in proton–proton collisions at and 8 TeV in the Compact Muon Solenoid experiment at the...
CMS | Higgs | Physics | PARTON DISTRIBUTIONS | SEARCH | PHYSICS, NUCLEAR | COLLIDERS | STANDARD MODEL | ELECTROWEAK CORRECTIONS | BROKEN SYMMETRIES | ASTRONOMY & ASTROPHYSICS | QCD CORRECTIONS | PP COLLISIONS | SPECTRUM | MODEL HIGGS-BOSON | PHYSICS, PARTICLES & FIELDS | Analysis | Collisions (Nuclear physics) | Searching | Elementary particles | Decay | Higgs bosons | Standard deviation | Solenoids | Standards | Bosons | Physics - High Energy Physics - Experiment | High Energy Physics - Experiment | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
CMS | Higgs | Physics | PARTON DISTRIBUTIONS | SEARCH | PHYSICS, NUCLEAR | COLLIDERS | STANDARD MODEL | ELECTROWEAK CORRECTIONS | BROKEN SYMMETRIES | ASTRONOMY & ASTROPHYSICS | QCD CORRECTIONS | PP COLLISIONS | SPECTRUM | MODEL HIGGS-BOSON | PHYSICS, PARTICLES & FIELDS | Analysis | Collisions (Nuclear physics) | Searching | Elementary particles | Decay | Higgs bosons | Standard deviation | Solenoids | Standards | Bosons | Physics - High Energy Physics - Experiment | High Energy Physics - Experiment | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
Journal Article